From Advisory Vote to Actual Rule: A Realistic Timeline for What Happens Next With BPC-157, TB-500 and the Other Peptides

This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use.

Everyone wants to know the same thing right now: when can these peptides actually be compounded under prescription? The honest answer is not for a while, and probably not until sometime in 2027 at the earliest. But “a while” isn’t a satisfying answer on its own, so here’s the actual sequence of steps between where things stand today and where they’d need to get to for anything practical to change.

How we got here

This didn’t start with the July vote. In April 2026, Health Secretary Robert F. Kennedy Jr. removed twelve peptides, including the ones now under review, from Category 2 of the 503A Bulks List. Category 2 is effectively a “do not compound” flag, so lifting it was what cleared the way for these compounds to go in front of the Pharmacy Compounding Advisory Committee at all. Without that step, July’s meeting wouldn’t have happened.

FDA then published a Federal Register notice confirming the PCAC meeting for 23-24 July 2026, opening a public docket that ended up attracting close to 1,900 comments before the hearing even started. That’s a genuinely high level of public engagement for an advisory committee meeting, and it tells you how much attention this category has been getting outside the regulatory world too.

Where things stand right now

The vote happened. Six peptides recommended, one rejected, every vote close. We’ve covered the detail of that elsewhere, so the short version here: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax all got a favourable recommendation from the committee, against the advice of the FDA’s own scientific staff.

That recommendation currently has zero legal effect. Nobody can compound any of these six peptides under 503A today, and nothing about this vote makes that legal tomorrow either. It’s a recommendation sitting in front of the FDA, and what the FDA does with it is the entire rest of this story.

What has to happen before anything changes

There are three steps left, and none of them can be skipped.

First, FDA has to decide whether to act on the recommendation at all.

It isn’t obligated to. The agency has departed from PCAC advice before, and it could choose to do the same here for any or all of the six peptides.

Second, if it does decide to act, FDA has to publish a Notice of Proposed Rulemaking. This is the document that formally proposes adding specific substances to the 503A Bulks List. It also opens a fresh public comment period, separate from the comments already submitted ahead of the July meeting, so this is a second opportunity for researchers, clinicians and the public to weigh in before anything is finalised.

Third, after reviewing those comments, FDA publishes a final rule.

That’s the point, and only that point, where a peptide is actually added to the 503A Bulks List and a compounding pharmacy has clear legal footing to prepare it under prescription.

Every source we’ve checked on typical rulemaking timelines lands somewhere in the same range: roughly eight months at the fast end, up to two years at the slow end, with most estimates clustering around twelve to eighteen months. Given that FDA hasn’t completed final rulemaking for the 503A Bulks List for more than about ten substances in the list’s entire history, there’s no strong reason to expect this batch to move through unusually quickly.

What happens if you fast-forward and it doesn’t work out

Worth being clear about this too: a final rule isn’t guaranteed. FDA could propose adding some peptides and not others, or decline to act on part of the list, or the process could stall entirely if priorities shift. The July vote is a recommendation moving through a process, not a countdown to a certain outcome.

The next PCAC meeting is already on the calendar

Here’s a detail most coverage of the July vote has missed entirely. FDA has already announced that the PCAC will meet again before the end of February 2027 to review five more peptides for the 503A list: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor. So this isn’t a one-off event. It’s the second stop in what looks like an ongoing, broader review of the peptide category, and it’s a reasonable bet that it won’t be the last.

The realistic version, in one paragraph

Nothing changes for BPC-157, TB-500 or the other four peptides in the short term. The earliest a compounding pathway becomes real is likely mid-to-late 2027, assuming the FDA decides to move forward at all, and that’s an optimistic reading of the typical timeline rather than a guaranteed one. In the meantime, a second round of five more peptides is already queued up for review in early 2027, which tells you this is very much the start of a longer process rather than a single event that’s already concluded.

We’ll update this timeline as each stage actually happens, rather than speculate ahead of it.

This article mentions BPC-157, KPV and TB500 If you are a researcher and want to purchase these for your research projects you can purchase them here.
BPC-157

KPV

TB-500